Fundraising Fox

Pete Olson

Executive at Iambic Therapeutics, Inc. · Chief Scientific Officer at Iambic

San Diego, California, United States

Find your path to Pete

289 people in our graph share verified history with Pete — schools, employers, funds. One of them is your warm intro.

Charles CallunlockedPete: together at University of California, Davis (1992)
×2Pete: together at UCSF
×2Pete: together at UC San Diego
×3Pete: together at The Salk Research Institute, Howard Hughes Medical Institute

About

Pete Olson, PhD, is the Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotechnology company that applies AI models for protein structure prediction and drug design alongside high-throughput chemistry and biology experimentation. He previously served as VP, Research at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in January 2024, where he led in vitro and in vivo biology and pharmacology functions for small molecule oncology programs, several of which reached the clinic, including adagrasib (KRAZATI), BMS-986504, MRTX1133, MRTX0902, and ORIC-944. Earlier, he was a Senior Group Leader in the Pfizer Oncology Research Unit and has more than 25 years of basic, pre-clinical, and translational research experience across academia and industry.

Executive at Iambic Therapeutics, Inc.

Intro paths

→

In turn, Pete can intro founders to Iambic Therapeutics, Inc.'s investors below.

Iambic Therapeutics, Inc.'s investors · 3

AbingworthLondon · $15M – $30M checks · since 2023Nexus Venture PartnersPort Louis, Port Louis · $500K – $10M checks · since 2023Nexus VenturesMenlo Park · since 2026

Co-founders at Iambic Therapeutics, Inc.

FM
Fred ManbyExecutive Officer, Director
TMThomas Miller
Thomas MillerExecutive Officer, Director

Chief Scientific Officer at Iambic

Intro paths

→

In turn, Pete can intro founders to Iambic's investors below.

Iambic's investors · 11

AbingworthLondon · $15M – $30M checksAlumni VenturesManchester · $100K – $10M checksAscenta CapitalWilmingtonCatalio Capital ManagementNew YorkCatalio Capital Management, LPNew YorkCoatue ManagementNew York · $1M – $20M checksEisai Innovation, Inc.San FranciscoFREEFLOWBerkeleyIllumina VenturesFoster CityNVIDIASanta Clara · since 2024OrbiMedNew York · $1M – $75M checks

Co-founders at Iambic

TMTom Miller
Tom MillerCo-Founder & CEO
FM
Fred ManbyCo-Founder & CTO
TMThomas Miller
Thomas MillerFounder

Experience

  1. Iambic TherapeuticsChief Scientific Officercurrent2024 — presentSan Diego, California, United States
  2. Bristol Myers SquibbVice President, Research2024San Diego, California, United States
  3. Mirati TherapeuticsVice President, Research2024San Diego, California, United States
  4. Mirati TherapeuticsExecutive Director of Research2022 — 2024San Diego, California, United States
  5. Mirati TherapeuticsSenior Director of Research2019 — 2022Greater San Diego Area
  6. Mirati TherapeuticsDirector of Research2015 — 2019Greater San Diego Area
  7. PfizerSenior Principal Scientist2014 — 2015La Jolla, CA
  8. PfizerPrincipal Scientist2009 — 2014La Jolla, CA
  9. UCSFPostdoc2005 — 2009
  10. The Salk Research Institute, Howard Hughes Medical InstituteGraduate Student1998 — 2005
  11. Gilead SciencesResearch Associate1996 — 1998
  12. GenentechSummer Intern1995

Skills & more

Signal Transduction10Pharmacology7Metabolic Syndrome2miRNAAngiogenesis2Drug Discovery21In Vivo20Translational Research12Cell Biology6Molecular Biology5In Vitro18Cancer7
+9 moreAnimal ModelsCancer ResearchOncologyTarget IdentificationBiomarkersCellProtein ChemistryProtein ExpressionLeadership

From Pete's professional profile.

Frequently asked questions

Who is Pete Olson?
Pete Olson, PhD, is the Chief Scientific Officer at Iambic Therapeutics, a clinical-stage biotechnology company that applies AI models for protein structure prediction and drug design alongside high-throughput chemistry and biology experimentation. He previously served as VP, Research at Mirati Therapeutics, which was acquired by Bristol Myers Squibb in January 2024, where he led in vitro and in vivo biology and pharmacology functions for small molecule oncology programs, several of which reached the clinic, including adagrasib (KRAZATI), BMS-986504, MRTX1133, MRTX0902, and ORIC-944. Earlier, he was a Senior Group Leader in the Pfizer Oncology Research Unit and has more than 25 years of basic, pre-clinical, and translational research experience across academia and industry.
Where does Pete Olson work?
Pete Olson is Executive at Iambic Therapeutics, Inc. and Chief Scientific Officer at Iambic.
Where did Pete Olson go to school?
Pete Olson studied at UC San Diego (PhD, Biology); University of California, Davis (BS, Biochemistry).

Same school

Also attended UC San Diego577

Elad GilSolo general partner investing through Gil CapitalMark SusterManaging Partner at Upfront VenturesChester NgGeneral Partner at AtomicBirgitteInvestor at InvestinorHouman HaghighiPartner, Business & Corporate Development at Menlo VenturesFreya Svedberg-KeatingInvestor at Medicxi

+ 571 more

Also attended University of California, Davis352

Charles CallSLP & Venture Partner at Cottonwood Technology FundDavid PhuController at Felicis VenturesTeresa ChanChief Financial Officer at Felicis VenturesBryan EglanDirector of Business Development at Menlo VenturesDennisDirector of Trading at Pantera CapitalScott MaxwellInvestor at OpenView Venture Partners

+ 346 more

Shared employers

Also worked at Bristol Myers Squibb156

Scott BillerInvestor at GV (Google Ventures)Avantika DaingFounding Partner at Plum Alley InvestmentsJake BauerVenture Partner at ARCH Venture PartnersScott DonohueSenior Director, Market Access at Deerfield Management CompanyMellissa GraySenior Scientist, Protein Sciences at Deerfield Management CompanyBeth SeidenbergFounding Managing Director at Westlake Village BioPartners

+ 150 more

Also worked at Mirati Therapeutics3

David MeekChief Executive Officer at Bluebird BioJamie DonadioExecutive Officer at Renibus TherapeuticsColleen SjogrenChief Commercial Officer at Nuvation Bio

Also worked at Pfizer401

Jigar RaythathaInvestor at Third Rock VenturesAbbie CelnikerInvestor at Third Rock VenturesErin MooreInvestor at Third Rock VenturesJeb KeiperInvestor at Third Rock VenturesRichard ChesworthInvestor at Third Rock VenturesMichael TaylorOperating Partner at Mission Biocapital

+ 395 more

Also worked at The Salk Research Institute, Howard Hughes Medical Institute33

Brittany de KouchkovskyDirector, University Relations at Osage University PartnersRichard HeymanVenture Partner at ARCH Venture PartnersMira ChaurushiyaManaging Director at Westlake Village BioPartnersChris WeyrerPrincipal at Vida VenturesDavid AmaralDirector Of The Autism Center Of Excellence At UC Davis at AIFRicha ChaturvediExecutive Assistant at Voyager Partners

+ 27 more